STAAR Surgical (NASDAQ:STAA) Stock Rating Lowered by William Blair

STAAR Surgical (NASDAQ:STAA) was downgraded by analysts at William Blair from an “outperform” rating to a “market perform” rating in a research note issued on Wednesday,Briefing.com Automated Import reports.

STAA has been the subject of several other research reports. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Tuesday, January 7th. Canaccord Genuity Group reduced their target price on shares of STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research note on Monday, December 9th. Finally, Stephens upgraded shares of STAAR Surgical to a “hold” rating in a research note on Monday, December 2nd. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, STAAR Surgical currently has an average rating of “Hold” and an average target price of $36.50.

STAAR Surgical Stock Performance

NASDAQ STAA opened at $21.88 on Wednesday. The firm has a 50-day simple moving average of $23.94 and a 200 day simple moving average of $29.33. STAAR Surgical has a twelve month low of $21.13 and a twelve month high of $52.68. The stock has a market cap of $1.08 billion, a PE ratio of 49.73 and a beta of 0.62.

Insiders Place Their Bets

In other news, major shareholder Broadwood Partners, L.P. acquired 53,500 shares of the company’s stock in a transaction dated Monday, December 16th. The stock was bought at an average price of $24.24 per share, with a total value of $1,296,840.00. Following the completion of the acquisition, the insider now owns 10,821,931 shares in the company, valued at approximately $262,323,607.44. This represents a 0.50 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders acquired a total of 105,876 shares of company stock worth $2,487,168 over the last quarter. Company insiders own 1.00% of the company’s stock.

Institutional Trading of STAAR Surgical

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of STAAR Surgical by 5.8% during the fourth quarter. Vanguard Group Inc. now owns 5,855,570 shares of the medical instruments supplier’s stock worth $142,232,000 after buying an additional 319,441 shares in the last quarter. LPL Financial LLC increased its holdings in shares of STAAR Surgical by 45.3% during the fourth quarter. LPL Financial LLC now owns 15,994 shares of the medical instruments supplier’s stock worth $388,000 after buying an additional 4,989 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of STAAR Surgical during the fourth quarter worth approximately $180,000. American Century Companies Inc. increased its holdings in shares of STAAR Surgical by 70.0% during the fourth quarter. American Century Companies Inc. now owns 13,256 shares of the medical instruments supplier’s stock worth $322,000 after buying an additional 5,457 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of STAAR Surgical during the fourth quarter worth approximately $278,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.